3,4-Dimethyl-pyridincarbonsaeure-(5) | 878794-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,4-Dimethyl-pyridincarbonsaeure-(5)
• 英文别名: 4,5-Dimethylpyridine-3-carboxylic acid
• CAS: 878794-22-0
• 化学式: C₈H₉NO₂
• 分子量: 151.165
• InChiKey: KPDANYHJEWJPQM-UHFFFAOYSA-N

物化性质

• 沸点：
  323.9±37.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] COMPOSÉS 6,7-DIHYDROPYRAZOLO[1,5-A] PYRAZIN-4(5H)-ONE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES NÉGATIFS DES RÉCEPTEURS MGLUR2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016016395A1

  公开（公告）日：2016-02-04

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及新型的6,7-二氢吡唑[1,5-a]吡嗪-4(5H)-酮衍生物，作为代谢型谷氨酸受体2型("mGluR2")的负变构调节剂(NAMs)。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的方法，以及使用这些化合物和组合物预防或治疗涉及代谢型受体mGluR2亚型的疾病。
• Process for producing poly (para-phenylene-sulfide)
  申请人：Tosoh Corporation

  公开号：EP0325061A2

  公开（公告）日：1989-07-26

  In a process for producing poly (p-phenylenesulfide) from an alkali metal sulfide and a p-dihalobenzene, a product polymer of an advantageously increased molecular weight is obtained by: providing a mixture comprising an alkali metal sulfide, a polar aprotic solvent and a carbox­ylic acid sodium salt represented by the general formula: ZCOONa (wherein Z is a C₆ - C₂₀ aromatic hydrocarbon group or a substituted or unsabstituted pyridyl group where substituents R, which may be the same or different, represent each a C₁ - C₂₀ organic radical and n is an integer of from 0 to 4), the content of water present in said mixture apart from any water of hydration or crystal­lization which may be contained in said alkali metal sulfide and carboxylic acid sodium salt being at least 5 moles per mole of said alkali metal sulfide present; thermally dehydrating said alkali metal sulfide in said mixture by removing at least part of the water from said mixture; and then contacting the resulting dehydrated mixture with a p-dihalobenzene so as to produce the intended polymer.

  在一种利用碱金属硫化物和对二卤代苯生产聚（对苯基硫醚）的工艺中，可通过以下方法获得分子量显著增加的聚合物产品：提供一种混合物，该混合物包括碱金属硫化物、极性壬烷溶剂和通式为 ZCOONa 的羧酸钠盐（其中 Z 为 C₆ - C₂₀ 芳烃基团或取代或未取代的吡啶基）：ZCOONa (其中 Z 是 C₆ - C₂₀ 芳烃基团或取代或未取代的吡啶基团) 其中，取代基 R（可以相同或不同）各代表一个 C₁ - C₂₀ 有机基，n 为 0 至 4 的整数），除了可能包含在所述碱金属硫化物和羧酸钠盐中的任何水合或结晶水之外，存在于所述混合物中的水的含量为每摩尔存在的所述碱金属硫化物至少 5 摩尔；通过从所述混合物中除去至少部分水分，对所述混合物中的所述碱金属硫化物进行热脱水；然后将得到的脱水混合物与对二卤代苯接触，以生产所需的聚合物。
• Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors
  申请人：Janssen Pharmaceutica NV

  公开号：US10005785B2

  公开（公告）日：2018-06-26

  The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

  本发明涉及式 (I) 的新型 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮衍生物 作为代谢型谷氨酸受体亚型 2（"mGluR2"）的负异位调节剂（NAMs）。本发明还涉及包含此类化合物的药物组合物、制备此类化合物和组合物的工艺，以及使用此类化合物和组合物预防或治疗涉及代谢型受体 mGluR2 亚型的疾病。
• TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS
  申请人：GENSET

  公开号：EP1412515A2

  公开（公告）日：2004-04-28
• NOVEL COMPOUNDS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20170121313A1

  公开（公告）日：2017-05-04

  The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.